VIVSVivoSim Labs, Inc.
The schedule
- Thu15Oct
Management is slated to present pipeline data. For a distressed micro-cap, strong clinical or preclinical data is the sole lever to attract a partner or acquire funding on favorable terms.
- Wed11Nov
Mandatory upcoming Q2 2026 earnings. Investors will focus squarely on the remaining cash balance and management's strategies for extending the runway, as the staggering -$5.76M net loss in the prior quarter underscores massive structural burn.
- Thu14Jan
Estimated Q3 2026 results. The focus will be entirely on survival metrics—cash runway exhaustion, debt covenants on the $447k load, and potential strategic alternatives—as operating cash flow continues to bleed.
- Mon15Feb
Given the unsustainable cash burn and sub-$2M market cap, securing a strategic partner or out-licensing asset rights is likely the only viable path to long-term survival and avoiding Chapter 11.
Past
- Tue15Sep
With cash reserves at $5.02M dwindling rapidly relative to the $2.23M quarterly operating cash burn, VIVS faces immediate funding needs. A highly dilutive equity raise or a reverse split to maintain exchange listing compliance is a substantial risk before the next earnings cycle.
